TNF and psoriasis vulgaris: The objectives of this study were (1) to compare skin homeostasis and barrier function in patients with psoriasis vulgaris before and during treatment with a tumor necrosis factor-α (TNF-α) inhibitor—adalimumab—and (2) to determine whether disease severity and patient-reported well-being improve over the course of therapy.